The CAR-TCR Summit remains at the forefront of the industry bringing you never-seen-before data from the movers and shakers in CAR and TCR therapy development.
Dedicated to discussing the next generation candidates beyond CD19, from solid tumor indications to autoimmune disorders, this meeting provides an in depth breakdown of the current strategies to optimize the durability, persistence and targeting of approved and novel therapies to reduce relapse rates and overcome toxicity.
At the premier, end-to-end summit focused on early research through to commercialization, join the experts to discuss how to streamline process development and logistics supply chains for affordable and accessible CAR-TCR therapeutics.
Take advantage of the unrivaled networking opportunities as we bring together over 1000 industry leaders developing CAR-TCR based therapies from across pharma, biotech, regulatory bodies, academia, solution and service providers.
"The CAR-TCR summit is an ideal size and attracts the key players in the field. Good opportunity for networking and getting the relevant updates about progress in the space." GSK
"This meeting is increasingly becoming the venue for significant breaking news in the field"
"This is a best in class and top summit in the CAR-TCR area which is an invaluable asset to both industry and academia"
University of Pennsylvania
2 Day Summit (Drug Developers) - Early Bird ends June 21st: USD 2499.0,
2 Day Summit (Drug Developers) - Final Online price : USD 2999.0,
2 Day Summit (Academics) - Early Bird ends June 21st: USD 1499.0,
2 Day Summit (Academics) - Final Online price : USD 1999.0
Speakers: James Noble, Chief Executive Officer, Adaptimmune ; Barbra Sasu, Chief Scientific Officer, Allogene Therapeutics ; Elsy Boglioli, Chief Operating Officer, Cellectis ; Katherine Szarama, Evidence Development Division, Centers for Medicare and Medicaid Services ; Peter Emtage Senior Vice President and Global Head of Cell Therapy Research, Kite, a Gilead Company; Pascal Touchon, Senior Vice President and Global Head of Cell and Gene, Novartis ; Jason Krentz, Chief Technology Officer, Tmunity Therapeutics ; Laurence Cooper, Chief Executive Officer, Ziopharm Oncology